Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation

Table 2

Top canonical pathways: significant molecular pathways regulated in HCC-R.

Up-regulated in HCC-R	P value	Genes
Cell cycle: G1/S checkpoint regulation	9.16𝐸−09	CDKN2B, E2F2, E2F5, GNL3, HDAC2, MDM2, MYC, PA2G4
RAN signaling	4.92𝐸−06	KPNA2, KPNB1, RANBP1, RCC1
Chronic myeloid leukemia signaling	4.89𝐸−05	E2F2, E2F5, HDAC2, MDM2, MYC, PA2G4
Molecular mechanisms of cancer	1.35𝐸−04	CDKN2B, E2F2, E2F5, FANCD2, FZD3, MDM2, MYC, PA2G4, PLCB1, PMAIP1
Cyclins and cell cycle regulation	2.22𝐸−04	CDKN2B, E2F2, E2F5, HDAC2, PA2G4
Downregulated in HCC-R	𝑃-value	Genes
Nicotine degradation II	3.41𝐸−04	FMO3, FMO4, INMT
FXR/RXR activation	1.05𝐸−03	FETUB, SLC10A1, SLC22A7
Complement system	2.69𝐸−03	C7, MASP1
Hepatic cholestasis	4.14𝐸−03	GCGR, SLC10A1, SLC22A7
Catecholamine biosynthesis	9.25𝐸−03	DBH